GRIFOLS S.A. (GRF.MC)
Collects blood plasma and makes medicines from it for treating diseases and disorders.
9.99+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-22.7%
The outlook
Grifols trades near the lower end of its 52-week range, with analysts broadly recommending a buy at an average target about 45% above the current price. The stock shows mixed technical positioning relative to its moving averages, though analyst sentiment leans constructive overall. Trailing P/E sits at 16.4.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 12 analysts
Price trendMixed vs its moving averages
52-week range30% of the way from its 52-week low to high
Price targetAvg target +45% vs current price
Analyst price target
~12-month · 12 analysts14.51average target+45.3% vs now
Now 9.99
Low 9.00High 20.80
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
13.70
52-wk low
8.43
50-day avg
9.17
200-day avg
10.05
Trailing P/E
16.4